Genentech CFO
Executive Summary
Genentech CFO Lou Lavigne will retire in March 2005 after serving as a Genentech finance exec for over 22 years. He first served as controller and was promoted to CFO in 1988. In his retirement, Lavigne intends to serve on the boards of other companies. Senior VP-Product Operations David Ebersman will replace Lavigne as CFO. Pat Yang, PhD, who serves as VP-South San Francisco manufacturing & engineering, will be promoted to senior VP-product operations. Yang joined the company from Merck in late 2003 (1"The Pink Sheet" Jan. 19, 2004, In Brief)...
You may also be interested in...
Genentech exec appointments
Hal Barron, MD, will head Genentech's newly formed development organization combining the medical affairs and developmental sciences departments. He was previously VP-medical affairs, and will continue to report to Chief Medical Officer Susan Hellmann, MD. Patrick Yang, PhD, joins Genentech from Merck as VP-South San Francisco manufacturing and engineering, reporting to Senior VP-Product Operations David Ebersman. At Merck, Yang was VP-Asia/Pacific Manufacturing Operations. Both positions are newly created...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.